Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Bicara Therapeutics has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Bicara Therapeutics's investors include TPG, RA Capital Management, Janus Henderson Investors, Deerfield Management, Biocon.
Bicara Therapeutics is headquartered in Cambridge, United States.
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Bicara Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bicara Therapeutics — Funding & Investors." VCBacked, February 24, 2026, https://www.vcbacked.co/company/bicara-therapeutics. Accessed July 20, 2026.
VCBacked. (2026). Bicara Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/bicara-therapeutics
{{cite web |title=Bicara Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/bicara-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated